CBIO earnings: next report 2026-07-30, real EPS beat/miss history, analyst consensus Buy, P/E -1.45. Updated 2026-07-23.
Crescent Biopharma (CBIO) Research Hub
Crescent Biopharma (CBIO) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 19.41 USD (-2.90%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.45, market cap 0.43B. This hub links to the full technical, earnings and options research available for CBIO.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 19.41 USD (-2.90%) |
| 52-week range | 13.99 USD – 22.33 USD |
| Trend regime | Range |
| 14-day RSI | 67.3 (Bullish) |
| Trailing P/E | -1.45 |
| Market cap | 0.43B |
| Dividend yield | 0.00% |
| Next earnings | 2026-07-30 |
Available research for CBIO
Covered Call on CBIO: how it works, illustrative setup around the real 19.41 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on CBIO: how it works, illustrative setup around the real 19.41 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on CBIO: how it works, illustrative setup around the real 19.41 USD price, max profit/loss, breakeven and when to use it. Educational.
CBIO technical analysis: range, last 19.41 USD, RSI 67.3, 52w range 13.99 USD–22.33 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is CBIO in?
Crescent Biopharma (CBIO) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is CBIO in an uptrend or downtrend?
As of 2026-09-11, CBIO is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is CBIO's trailing P/E ratio?
CBIO's trailing P/E is -1.45, with a market cap of 0.43B. See the earnings research page for full valuation detail.
When does CBIO next report earnings?
CBIO is next scheduled to report earnings on 2026-07-30, with a consensus EPS estimate of -0.7 USD.